We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov Menu

The Growth Factor Signature (GFS) as an Intermediate Biomarker of Response for Development of PI3K-Pathway Inhibitors in Patients With Breast Cancer (MK-8669-050)

This study has been completed.
ClinicalTrials.gov Identifier:
First Posted: October 14, 2010
Last Update Posted: January 21, 2015
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.
This clinical trial will evaluate whether treatment with ridaforolimus, dalotuzumab, or ridforolimus/dalotuzumab combination therapy reduces Growth Factor Signature (GFS) Score among participants with breast cancer.

Condition Intervention Phase
Breast Cancer Drug: Ridaforolimus + Dalotuzumab Drug: Ridaforolimus Drug: Dalotuzumab Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Clinical Trial to Qualify the Growth Factor Signature (GFS) as an Intermediate Biomarker of Response for Development of PI3K-Pathway Inhibitors in Patients With Breast Cancer

Resource links provided by NLM:

Further study details as provided by Merck Sharp & Dohme Corp.:

Primary Outcome Measures:
  • The population mean change from baseline in GFS (Growth Factor Signature) score [ Time Frame: Baseline and Day 15 ]

Secondary Outcome Measures:
  • The population mean change from baseline in Ki67 among participants receiving ridaforolimus/dalotuzumab combination therapy [ Time Frame: Baseline and Day 15 ]
  • The correlation between change in Ki67 expression and change in GFS after two weeks of treatment with ridaforolimus/dalotuzumab (MK-8669/MK-0646) combination therapy, ridaforolimus (MK-8669) monotherapy and/or dalotuzumab (MK-0646) monotherapy [ Time Frame: Baseline and Day 15 ]

Enrollment: 63
Study Start Date: September 2010
Study Completion Date: December 2012
Primary Completion Date: December 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Ridaforolimus + Dalotuzumab
Ridaforolimus (MK-8669) + Dalotuzumab (MK-0646)
Drug: Ridaforolimus + Dalotuzumab
Ridaforolimus (MK-8669) once daily for 5 consecutive days per week and Dalotuzumab (MK-0646) intravenously (IV) once weekly for 2 weeks
Other Name: MK-8669, MK-0646
Experimental: Ridaforolimus
Ridaforolimus (MK-8669)
Drug: Ridaforolimus
Ridaforolimus 40 mg (once daily for 5 consecutive days per week) for 2 weeks, 10 mg enteric-coated tablets
Other Name: MK-8669
Experimental: Dalotuzumab
Dalotuzumab (MK-0646)
Drug: Dalotuzumab
Dalotuzumab, intravenously (IV) at 10 mg/kg/week for 2 weeks
Other Name: MK-0646


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Participant has operable Stage I-IIIa invasive breast cancer of the following subtype: ER-positive, HER2-negative tumor with histologic grade 2 or 3 and Ki67 ≥ 15%
  • Tumor is at least 2 cm in diameter as assessed by physical or radiographic exam
  • Participant consents to provide an existing tissue sample or to have a core needle biopsy before drug administration
  • Participant consents to provide tissue samples following drug administration by a second core needle biopsy or from a surgical specimen
  • Participant must have adequate organ function

Exclusion Criteria:

  • Participant has received any prior chemotherapy, biological therapy or radiotherapy for breast cancer
  • Participant has a known hypersensitivity to the components of study drugs or their analogs, including hypersensitivity to macrolide antibiotics (e.g. clarithromycin, erythromycin, azithromycin).
  • Participant has poorly controlled diabetes mellitus, or requires insulin for glucose control.
  • Participant is unable to swallow capsules and/or absorb oral medications
  • Participant is pregnant or breastfeeding, or expecting to conceive children within the projected duration of the study.
  • Participant is known to be Human Immunodeficiency Virus (HIV)-positive
  • Participant has known history of active Hepatitis B or C.
  • Participant is concurrently using growth hormone (GH) or growth hormone inhibitors
  • Participant has significant or uncontrolled cardiovascular disease, including heart failure, unstable angina, or a myocardial infarction within the last 6 months
  Contacts and Locations
No Contacts or Locations Provided
  More Information

Responsible Party: Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier: NCT01220570     History of Changes
Other Study ID Numbers: 8669-050
First Submitted: October 12, 2010
First Posted: October 14, 2010
Last Update Posted: January 21, 2015
Last Verified: January 2015

Keywords provided by Merck Sharp & Dohme Corp.:
breast cancer
ridaforolimus/dalotuzumab combination therapy

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases
Antibodies, Monoclonal
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Anti-Bacterial Agents
Anti-Infective Agents
Antibiotics, Antineoplastic
Antineoplastic Agents
Antifungal Agents
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs